Related Experiment Video

Updated: May 20, 2026

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development
09:37

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development

Published on: March 5, 2017

Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells

Mahru C An1, Ningzhe Zhang, Gary Scott

  • 1The Buck Institute for Research on Aging, Novato, CA 94945, USA.

Cell Stem Cell
|July 4, 2012
PubMed

Insights

Researchers genetically corrected Huntington's disease (HD) patient cells. Corrected cells developed into neurons, showing normalized disease pathways and reversed phenotypes, offering hope for cell replacement therapy.

Area of Science:

  • Neuroscience
  • Genetics
  • Stem Cell Biology

Background:

  • Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene.
  • This expansion leads to polyglutamine tract elongation, resulting in striatal neuron cell death in HD patients.

Purpose of the Study:

  • To genetically correct human induced pluripotent stem cells (iPSCs) derived from Huntington's disease patients.
  • To assess the functional and phenotypic correction of these cells following differentiation into neurons.
  • To evaluate the potential of corrected iPSCs for disease modeling and cell replacement therapy.

Main Methods:

  • Utilized homologous recombination to replace the expanded CAG repeat in HD patient-derived iPSCs with a normal repeat.
  • Differentiated corrected and uncorrected iPSCs into DARPP-32-positive neurons in vitro.
  • Assessed neuronal differentiation, signaling pathway normalization (cadherin, TGF-β, BDNF, caspase activation), and mitochondrial bioenergetics in vitro and in vivo.

Main Results:

  • Successfully corrected the expanded CAG repeat in HD patient iPSCs, with correction persisting through neuronal differentiation.
  • Corrected iPSCs differentiated into DARPP-32-positive neurons that exhibited normalized pathogenic signaling pathways.
  • Disease phenotypes, including susceptibility to cell death and altered mitochondrial bioenergetics, were reversed in corrected neural stem cells.

Conclusions:

  • Genetically corrected patient-specific iPSCs provide a valuable model for studying Huntington's disease in an identical genetic background.
  • Correction of the genetic defect in iPSCs reverses key disease phenotypes and normalizes aberrant signaling pathways.
  • This approach represents a critical advancement towards the potential use of genetically corrected iPSCs in Huntington's disease cell replacement therapy.

More Related Videos

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells09:04

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Published on: September 25, 2019

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...